ES2038181T3 - Composiciones farmaceuticas de liberacion sostenida en forma de dosificacion oral. - Google Patents

Composiciones farmaceuticas de liberacion sostenida en forma de dosificacion oral.

Info

Publication number
ES2038181T3
ES2038181T3 ES198787305872T ES87305872T ES2038181T3 ES 2038181 T3 ES2038181 T3 ES 2038181T3 ES 198787305872 T ES198787305872 T ES 198787305872T ES 87305872 T ES87305872 T ES 87305872T ES 2038181 T3 ES2038181 T3 ES 2038181T3
Authority
ES
Spain
Prior art keywords
oral dosage
pharmaceutical compositions
dosage form
sustained release
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787305872T
Other languages
English (en)
Inventor
Claire Jacqueline Lovegrove
Anthony John Phillips
David Alexander Rawlins
David Alexander Tainsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2038181T3 publication Critical patent/ES2038181T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LAS FORMAS DE DOSIFICACION ORAL PARA SALES NEUTRAS, DE ION HIBRIDO O SALES DE FARMACOS ACIDOS O BASICOS CON UNA CINETICA DE LIBERACION DEL ORDEN APROXIMADO DE CERO, COMPRENDEN UNA MATRIZ NUCLEO DEL FARMACO Y UN POLIMERO GELIFICANTE, ESTANDO LA MATRIZ RECUBIERTA CON UN POLIMERO PERMEABLE AL AGUA PERO INSOLUBLE.
ES198787305872T 1986-07-09 1987-07-02 Composiciones farmaceuticas de liberacion sostenida en forma de dosificacion oral. Expired - Lifetime ES2038181T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868616669A GB8616669D0 (en) 1986-07-09 1986-07-09 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2038181T3 true ES2038181T3 (es) 1993-07-16

Family

ID=10600761

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787305872T Expired - Lifetime ES2038181T3 (es) 1986-07-09 1987-07-02 Composiciones farmaceuticas de liberacion sostenida en forma de dosificacion oral.

Country Status (17)

Country Link
US (1) US4919938A (es)
EP (1) EP0253541B1 (es)
JP (1) JP2528130B2 (es)
KR (1) KR880001288A (es)
AT (1) ATE67408T1 (es)
AU (1) AU598280B2 (es)
CA (1) CA1303502C (es)
DE (1) DE3773070D1 (es)
DK (1) DK352387A (es)
ES (1) ES2038181T3 (es)
GB (1) GB8616669D0 (es)
GR (1) GR3002755T3 (es)
IE (1) IE59786B1 (es)
IL (1) IL83017A0 (es)
NZ (1) NZ220875A (es)
PT (1) PT85213B (es)
ZA (1) ZA874960B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
EP0325086A3 (en) * 1987-11-23 1990-10-31 Jago Research Ag Novel methods for obtaining therapeutic systems with controlled release of the drug
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
FR2640876B1 (es) * 1988-12-28 1993-09-24 Jouveinal Sa
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US4931286A (en) * 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
EP0664118B1 (en) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
CA2152795C (en) * 1992-12-30 1999-02-16 Victor Louis King Readily available konjac glucomannan sustained release excipient
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
AU736748B2 (en) * 1996-12-20 2001-08-02 Reckitt Benckiser France Improvements in or relating to packaging
WO1998041210A1 (fr) * 1997-03-14 1998-09-24 Toray Industries, Inc. Preparation de derive de prostaglandine i a liberation prolongee
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) * 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
CN1596128A (zh) * 2001-11-30 2005-03-16 辉瑞产品公司 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物
US20040137052A1 (en) * 2001-12-25 2004-07-15 Yoshihiro Uchiyama Acid-containing preparations
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
US20120034276A1 (en) * 2009-03-25 2012-02-09 Aska Pharmaceutical Co., Ltd. Solid preparation
US10945984B2 (en) * 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
JPS5659707A (en) * 1979-10-19 1981-05-23 Toyo Jozo Co Ltd Lasting antibiotic pharmaceutical and its preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4505890A (en) 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
FR2556965B1 (fr) 1983-12-21 1986-08-22 Rhone Poulenc Sante Nouvelle forme galenique du ketoprofene a liberation controlee
HU193979B (en) * 1984-06-12 1987-12-28 Sandoz Ag Process for producing naphtoxazine derivatives and pharmaceutical compositions containing them
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
AU592065B2 (en) * 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
IT1213080B (it) * 1986-06-17 1989-12-07 Recordati Chem Pharm Sistemi terapeutico per la cessione controllata di farmaci.

Also Published As

Publication number Publication date
PT85213A (en) 1987-07-01
JPS6323814A (ja) 1988-02-01
CA1303502C (en) 1992-06-16
DK352387D0 (da) 1987-07-08
EP0253541A2 (en) 1988-01-20
ZA874960B (en) 1988-08-31
JP2528130B2 (ja) 1996-08-28
EP0253541A3 (en) 1988-04-27
AU7534087A (en) 1988-01-14
US4919938A (en) 1990-04-24
IE59786B1 (en) 1994-04-06
PT85213B (pt) 1990-03-30
NZ220875A (en) 1990-11-27
ATE67408T1 (de) 1991-10-15
GB8616669D0 (en) 1986-08-13
DE3773070D1 (de) 1991-10-24
KR880001288A (ko) 1988-04-22
AU598280B2 (en) 1990-06-21
EP0253541B1 (en) 1991-09-18
DK352387A (da) 1988-01-10
IE871830L (en) 1988-01-09
IL83017A0 (en) 1987-12-20
GR3002755T3 (en) 1993-01-25

Similar Documents

Publication Publication Date Title
ES2038181T3 (es) Composiciones farmaceuticas de liberacion sostenida en forma de dosificacion oral.
AT400295B (de) Orale feste pharmazeutische dosierungsform mit programmierter wirkstofffreisetzung und verfahren zu ihrer herstellung
DE3650657D1 (de) Pharmazeutische Formulierung mit gesteuerter Freigabe
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DE69212882D1 (de) Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung
DE3773442D1 (de) Dosierungsform zur verabreichung eines medikaments mit mitteln zur regelung der loeslichkeit.
ATE71837T1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
FI951357A (fi) Farmaseuttiset koostumukset, jotka mahdollistavat trimetatsidiinin hidastetun vapautumisen oraalisen annostuksen jälkeen
ATE87201T1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
SE8803822D0 (sv) Novel dosage form
DK324687A (da) Transdermalt farmeceutisk praeparat
DE68902300D1 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
NO892764D0 (no) Medikamentell administreringsform for droevtyggere.
DE3681856D1 (de) Pharmazeutische 2-oxopyrrolidinverbindungen, ihre salze und ihre herstellung.
ATE32980T1 (de) Tabletten mit ph-unabhaengiger kontrollierter freisetzung.
DE3772965D1 (de) Imidazol-derivate mit therapeutischer aktivitaet, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE10095T1 (de) 10-substituierte 5-cyanmethylen-10,11-dihydrodibenzo-(a,d)-cycloheptene, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
NO910903D0 (no) Orale farmasoeytiske preparater med selektiv frigjoering i tykktarmen.
ATA26286A (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstoffreisetzung
IS4288A (is) 2,4-dísúlfónýlfenýlbútýlnítrón, sölt þess, lyfjablanda ásamt notkun á þessu efnasambandi við framleiðslu á lyfi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 253541

Country of ref document: ES